This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ajani, J. A. Search for Related Content PubMed PubMed Citation Articles by Ajani, J. A.

Evolving Chemotherapy for Advanced Gastric Cancer

University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Key Words. Gastric cancer • Taxane • Paclitaxel • Docetaxel • Oxaliplatin • Irinotecan • S-1 • Capecitabine

Correspondence: Jaffer A. Ajani, M.D., University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 426, Houston, Texas 77030, USA. Telephone: 713-792-2828; Fax: 713-745-1163; e-mail: jajani{at}mdanderson.org

Gastric cancer is the fourth most commonly diagnosed cancer and is the second leading cause of cancer death worldwide. More than 50% of patients undergo surgery, but even after a curative resection, 60% of patients relapse locally or with distant metastases. Despite the fact that many advances have occurred in the management of gastric cancer, it continues to carry a poor prognosis, amplifying the importance of palliative chemotherapy. When compared with best supportive care alone, combination chemotherapy yields a significant advantage in the management of advanced gastric cancer. However, no single regimen has emerged or been accepted as clearly superior over another. Numerous phase II studies have demonstrated promising results with newer agents including irinotecan, docetaxel, capecitabine, S-1, and oxaliplatin. Recently reported phase III results with these agents now demonstrate positive developments in the treatment options for patients with advanced gastric cancer.

This article has been cited by other articles:

				Z.-S. Zhao, Y.-Y. Wang, Y.-Q. Chu, Z.-Y. Ye, and H.-Q. Tao SPARC Is Associated with Gastric Cancer Progression and Poor Survival of Patients Clin. Cancer Res., January 1, 2010; 16(1): 260 - 268. [Abstract] [Full Text] [PDF]

				Y. Liu, Y. Ling, W. Hu, L. Xie, L. Yu, X. Qian, B. Zhang, and B. Liu The Herb Medicine Formula 'Chong Lou Fu Fang' Increases the Cytotoxicity of Chemotherapeutic Agents and Down-regulates the Expression of Chemotherapeutic Agent Resistance-related Genes in Human Gastric Cancer Cells In Vitro Evid. Based Complement. Altern. Med., October 29, 2009; (2009) nep175v1. [Abstract] [Full Text] [PDF]

				L. Celio, C. N. Sternberg, R. Labianca, I. La Torre, V. Amoroso, C. Barone, G. Pinotti, S. Cascinu, F. Di Costanzo, G. L. Cetto, et al. Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study Ann. Onc., June 1, 2009; 20(6): 1062 - 1067. [Abstract] [Full Text] [PDF]

				H. KONISHI, S. KIKUCHI, T. OCHIAI, H. IKOMA, T. KUBOTA, D. ICHIKAWA, H. FUJIWARA, K. OKAMOTO, C. SAKAKURA, T. SONOYAMA, et al. Latrunculin A Has a Strong Anticancer Effect in a Peritoneal Dissemination Model of Human Gastric Cancer in Mice Anticancer Res, June 1, 2009; 29(6): 2091 - 2097. [Abstract] [Full Text] [PDF]

				W. Li, C.-P. Yu, J.-t. Xia, L. Zhang, G.-X. Weng, H.-q. Zheng, Q.-l. Kong, L.-j. Hu, M.-S. Zeng, Y.-x. Zeng, et al. Sphingosine Kinase 1 Is Associated with Gastric Cancer Progression and Poor Survival of Patients Clin. Cancer Res., February 15, 2009; 15(4): 1393 - 1399. [Abstract] [Full Text] [PDF]

				N. F. Aykan and E. Idelevich The role of UFT in advanced gastric cancer Ann. Onc., June 1, 2008; 19(6): 1045 - 1052. [Abstract] [Full Text] [PDF]

				J Lee, T Lim, J. Uhm, K. Park, S. Park, S. Lee, J. Park, Y. Park, H. Lim, T. Sohn, et al. Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma Ann. Onc., May 1, 2007; 18(5): 886 - 891. [Abstract] [Full Text] [PDF]

				J Lee, W. Kang, J. Kwon, S. Oh, H. Lee, H. Kim, B. Park, H. Lim, M. Han, J. Park, et al. Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma Ann. Onc., January 1, 2007; 18(1): 88 - 92. [Abstract] [Full Text] [PDF]

				W Ichikawa and Y Sasaki Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients Ann. Onc., November 1, 2006; 17(11): 1665 - 1672. [Abstract] [Full Text] [PDF]

				M Orditura, E Martinelli, G Galizia, C Carlomagno, G Aurilio, L Vecchione, E. Lieto, S De Placido, G Catalano, F Ciardiello, et al. Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study Ann. Onc., October 1, 2006; 17(10): 1529 - 1532. [Abstract] [Full Text] [PDF]